Iovance Biotherapeutics Inc(IOVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.72 | Insider Own | 12.96% | Shs Outstand | 453.0M | Perf Week | 3.45% |
| Market Cap | 6.38B | Forward P/E | - | EPS next Y | 61.46% | Insider Trans | - | Shs Float | 394.3M | Perf Month | 30.46% |
| Enterprise Value | 6.13B | PEG | - | EPS next Q | -0.08 | Inst Own | 57.8% | Short Float | 16.44% | Perf Quarter | 187.55% |
| Income | -0.29B | P/S | 19.64 | EPS this Y | 59.29% | Inst Trans | 5.15% | Short Ratio | 3.94 | Perf Half Y | 309.59% |
| Sales | 0.32B | P/B | 8.67 | EPS next 5Y | - | ROA | -31.76% | Short Interest | 64.83M | Perf YTD | 416.12% |
| Book/sh | 1.62 | P/C | 21.44 | EPS past 3/5Y | 23.93% 10.23% | ROE | -40.36% | 52W High | -8.33% ($15.37) | Perf Year | 543.38% |
| Cash/sh | 0.66 | P/FCF | - | Sales past 3/5Y | - | ROIC | -37.15% | 52W Low | 700.57% ($1.76) | Perf 3Y | 308.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 41.2% | Gross Margin | 37.14% | Volatility(W/M) | 6.76% 7.06% | Perf 5Y | -44.98% |
| Dividend TTM | - | EV/Sales | 18.87 | Sales Y/Y TTM | 34.52% | Oper. Margin | -91.17% | ATR (14) | 0.9 | Perf 10Y | 118.45% |
| Dividend Ex-Date | - | Quick Ratio | 3.82 | EPS Q/Q | 68.51% | Profit Margin | -89.11% | RSI (14) | 59.32 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.35 | Sales Q/Q | 65.65% | SMA20 | 0.57% ($14.01) | Beta | 0.81 | Target Price | $14.4 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/6 | SMA50 | 29.16% ($10.91) | Rel Volume | 0.47 | Prev Close | $14.14 |
| Employees | 975 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 17.6% 13.07% | SMA200 | 151.99% ($5.59) | Avg Volume(3M) | 16.46M | Price | $14.09 |
| IPO | 2009/9/1 | Option/Short | Yes/Yes | Trades | 29305 | Volume | 7,760,523 | Change | -0.35% |
🧬 This is a U.S. biotech company that develops and commercializes tumor-infiltrating lymphocyte (TIL)-based cell therapies. It uses cell therapies derived from patients' own immune cells to treat solid tumors such as melanoma, and maintains a commercialized product along with a pipeline for indication expansion. The company has established itself as a differentiated cancer biotech leveraging the unique TIL cell therapy approach.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
IOVA has a sound balance sheet but weak earning power
Of every $100 in sales, $91.17 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,964. Peers typically go for $1,510.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -45.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 57.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #39 of 595 in the industry
Based on market cap of $6B.
IOVA#39 Iovance Biotherapeutics Inc $6B PER - 
RYTM#40 Rhythm Pharmaceuticals Inc $6B PER - 
LGND#41 Ligand Pharmaceuticals Inc $6B PER 32.5 
BLTE#42 Belite Bio Inc ADR $6B PER - 
IMVT#43 Immunovant Inc $6B PER - 
FAQ
What kind of company is IOVA?
IOVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IOVA?
The market cap of IOVA is approximately $6.4B, ranking 1,179 within its sector.
What is the 52-week high and low for IOVA?
IOVA has recorded a 52-week high of $15.37 and a low of $1.76.
